Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (DE:2LB)
FRANKFURT:2LB
RESEARCH TOOLSreports
2LB Stock Chart & Stats
Day’s Range― - ―
52-Week Range€3.17 - €13.60
Previous CloseN/A
Volume0.00
Average Volume (3M)519.00
Market Cap
$1.08B
Enterprise Value€1.99B
Total Cash (Recent Filing)$311.80K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.98
Next Earnings
May 13, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding327,876,700
10 Day Avg. Volume134
30 Day Avg. Volume519
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.07
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit49.67
Enterprise Value/Ebitda-5.49
Forecast
1Y Price Target
€18.31Price Target Upside490.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
---
Iovance Biotherapeutics News
PremiumCompany Announcements
Iovance Biotherapeutics’ Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
Iovance Biotherapeutics Reports Strong 2024 Earnings---
Bulls Say, Bears Say
Bulls Say
Market ExpansionIovance Biotherapeutics plans to accelerate growth by focusing on entering ex-U.S. markets such as the U.K., E.U., and Canada.
Product DemandStrong Proleukin sales indicate rapid and sustained demand for AMTAGVI, suggesting potential growth in the upcoming year.
Revenue PerformanceThe company reported revenue results higher than both internal and consensus estimates.
Bears Say
Adoption ChallengesThere are two schools of thought regarding the use of TIL, with some favoring later use due to side effects and complicated processes, which could impact adoption rates.
Product Revenue ConcernsThe stock is down approximately 20% post-close because of perceived Amtagvi revenue slowdown.
Revenue MissQ4 Amtagvi revenue of $49MM missed consensus of $55MM by 11%.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.30% Insiders
16.72%
Mutual Funds
33.12% Other Institutional Investors
34.27% Public Companies and
Individual Investors
2LB FAQ
What was Iovance Biotherapeutics Inc’s price range in the past 12 months?
Iovance Biotherapeutics Inc lowest stock price was €3.17 and its highest was €13.60 in the past 12 months.
What is Iovance Biotherapeutics Inc’s market cap?
Iovance Biotherapeutics Inc’s market cap is $1.08B.
When is Iovance Biotherapeutics Inc’s upcoming earnings report date?
Iovance Biotherapeutics Inc’s upcoming earnings report date is May 13, 2025 which is in 41 days.
How were Iovance Biotherapeutics Inc’s earnings last quarter?
Iovance Biotherapeutics Inc released its earnings results on Feb 27, 2025. The company reported -€0.24 earnings per share for the quarter, beating the consensus estimate of -€0.248 by €0.007.
Is Iovance Biotherapeutics Inc overvalued?
According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued.
Does Iovance Biotherapeutics Inc pay dividends?
Iovance Biotherapeutics Inc does not currently pay dividends.
What is Iovance Biotherapeutics Inc’s EPS estimate?
Iovance Biotherapeutics Inc’s EPS estimate is -0.22.
How many shares outstanding does Iovance Biotherapeutics Inc have?
Iovance Biotherapeutics Inc has 327,876,700 shares outstanding.
What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?
Iovance Biotherapeutics Inc reported an EPS of -€0.24 in its last earnings report, beating expectations of -€0.248. Following the earnings report the stock price went down -22.809%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?
Currently, no hedge funds are holding shares in DE:2LB
---
Iovance Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€18.31 (490.50% Upside)
€18.31 (490.50% Upside)
Blogger Sentiment
Bullish
DE:2LB Sentiment 88%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $503.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.53%
12-Months-Change
Fundamentals
Return on Equity
-57.48%
Trailing 12-Months
Asset Growth
16.67%
Trailing 12-Months
Company Description
Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
---
2LB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call demonstrated strong revenue performance and positive market adoption for Amtagvi, with significant highlights in manufacturing capacity and pipeline progress. However, high operating costs and the need for acceleration in adoption at ATCs present challenges.Read More>---
2LB Stock 12 Month Forecast
Average Price Target
€18.31
▲(490.50% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
Ardelyx
―
Viridian Therapeutics
―
Syndax Pharmaceuticals
―
89bio
―
Best Analysts Covering 2LB
1 Year
1 Year Success Rate
15/33 ratings generated profit
1 Year Average Return
+16.72%
reiterated a buy rating last month
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +16.72% per trade.
---